The One Health Company Featured at The World Economic Forum


Christina Lopes, the CEO and co-founder of The One Health Company, got a unique opportunity to raise the profile of her Philadelphia life science startup with an appearance at the World Economic Forum in Davos, Switzerland in January 2017.

A Young Global Leaders of World Economic Forum alumnus, Lopes was invited to attend the World Economic Forum Healthcare Steering Committee meeting there.

The One Health Company seeks to use pet dogs and cats suffering from the kinds of conditions that pharmaceutical companies are developing treatments for in humans, such as bone cancer, lymphoma, osteosarcoma, for animal trials as part of drug development. The rationale is that the canine genome more closely resembles humans than, say, the mouse genome.

The company also provides a more humane way to do animal testing than labs since the animals are cared for by their human parents. Pet owners have a strong sense of when their pets aren’t feeling well. Thus, the idea is that they’re well positioned to observe how their pets respond to these treatments. They can take note of that behavior through apps provided by the startup.  Pharma companies value that data to support their research and development work.

The agenda for the World Economic Forum Healthcare Steering Committee was formidable. How can the world deliver healthy lives and healthcare for 9.7 billion people by 2050? The group focused on topics such as precision medicine, affordable innovation, consumerization of health, health security and antimicrobial resistance.GettyImages-480094450-600x408

Lopes noted that the key themes at Davos this year were the Fourth Industrial Revolution and Responsive Leadership. There were many discussions around gender equity, inequality with technology underpinning those themes.

Facebook also spotlighted the company at Davos. Chris Norton of Facebook interviewed Lopes about the company in a live session on the social network. You can check out the interview here.

 Read the full article at MedCity News